Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial: European Urology

B.I. Rini, R.J. Motzer, T. Powles, D.F. McDermott, B. Escudier, F. Donskov, R. Hawkins, S. Bracarda, J. Bedke, U. De Giorgi, C. Porta, A. Ravaud, F. Parnis, E. Grande, W. Zhang, M. Huseni, S. Carroll, R. Sufan, C. Schiff, M.B. Atkins

Research output: Contribution to journalArticle

Cite this

Rini, B. I., Motzer, R. J., Powles, T., McDermott, D. F., Escudier, B., Donskov, F., Hawkins, R., Bracarda, S., Bedke, J., De Giorgi, U., Porta, C., Ravaud, A., Parnis, F., Grande, E., Zhang, W., Huseni, M., Carroll, S., Sufan, R., Schiff, C., & Atkins, M. B. (2020). Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial: European Urology. Eur. Urol.. https://doi.org/10.1016/j.eururo.2020.06.021